U.S. Machinery Stock News

Axogen (AXGN) just cleared a major regulatory hurdle, with the FDA approving its Biologics License Application for the AVANCE acellular nerve allograft, expanding indications and sharpening investor focus on the company’s potential growth opportunities. See our latest analysis for Axogen. That backdrop helps explain why, even after a modest 1 day share price pullback, Axogen’s 30 day share price return of 24.63 percent and 1 year total shareholder return of 99.12 percent signal strong,...

On December 5, 2025, ABM Industries’ board appointed Mr. Hytinen to its Audit Committee, adding further financial oversight experience to the company’s governance structure. This governance change comes alongside increasing institutional interest and research coverage, highlighting how ABM’s board composition is evolving as investor attention grows. Next, we’ll examine how growing institutional interest and new analyst coverage may influence ABM’s existing investment narrative and risk...

Carvana is being added to the S&P 500 on December 22, 2025, following a year marked by record Q3 2025 retail sales, improved profitability, and a widely cited operational turnaround in its online used-car platform. At the same time, insider share sales and mixed analyst views on valuation highlight that enthusiasm around Carvana’s index inclusion and growth story is paired with ongoing debates about risk and sustainability. We’ll now examine how Carvana’s upcoming S&P 500 inclusion may...

Ryman Hospitality Properties (RHP) increased its fourth quarter cash dividend to $1.20 per share, a move that signals management’s confidence in cash flows and draws new attention to the stock’s income profile. See our latest analysis for Ryman Hospitality Properties. The higher payout lands at a time when sentiment has been mixed, with the share price at $98.81 and a slightly negative year to date share price return. However, a strong five year total shareholder return hints that long term...

Kinder Morgan recently issued guidance projecting net income attributable to the company of US$2.90 billion in 2025 and US$3.10 billion in 2026, alongside a projected annualized 2026 dividend of US$1.19 that would mark its ninth consecutive year of dividend increases. This combination of higher expected earnings and continued dividend growth underscores Kinder Morgan’s emphasis on cash generation and capital returns within its fee-based infrastructure model. Next, we’ll explore how Kinder...

Global Payments (GPN) has been grinding through a challenging year, with the stock down roughly 27% in 2024 even as revenue and net income continue to inch higher. Investors are asking whether this gap signals opportunity. See our latest analysis for Global Payments. Despite the tough year to date, the recent 7 day and 30 day share price returns of 4.8% and 10.2% suggest sentiment is stabilising, even as the 1 year total shareholder return remains firmly negative. If this shift in momentum...

Earlier this week, investors learned that Google is testing mobile-first home-for-sale ads with built-in listing details, tour requests, and scheduling tools that overlap with Zillow’s Premier Agent experience and could reshape how buyers and sellers find real estate online. At the same time, Zillow is juggling listing-feed tensions with Chicago’s MLS and reevaluating climate-risk disclosures, highlighting pressures on its data advantages and agent relationships. We’ll now examine how...

Oscar Health recently gained fresh analyst coverage from Stephens & Co., which highlighted its technology-focused approach to Affordable Care Act exchanges, while the company also secured an agreement that will add Broward Health’s providers and facilities to its South Florida network starting in 2026. This combination of greater Wall Street attention and a broader provider network could influence how investors assess Oscar’s growth potential and competitive positioning in the ACA...

Mineralys Therapeutics (MLYS) just got a credibility boost, with its Phase 3 Launch HTN trial of lorundrostat featured in JAMA’s inaugural Research of the Year Roundup, spotlighting its approach to treatment resistant hypertension. See our latest analysis for Mineralys Therapeutics. Despite the recent recognition in JAMA, Mineralys’ share price return has cooled in the near term, with a weaker 1 month share price return and modest 3 month share price return. However, its year to date share...

Bread Financial Holdings recently increased its equity buyback authorization by US$200 million to a total of US$400 million, completed a US$60 million repurchase of 977,641 shares, and approved a 10% rise in its quarterly dividend to US$0.23 per share, paid on December 12, 2025. Together, the larger repurchase program and higher dividend highlight a stronger emphasis on returning capital to shareholders and management’s confidence in the company’s financial flexibility. We’ll now examine how...

Camping World Holdings (CWH) has had a rough stretch lately, with the stock sliding over the past 3 months and year, and that kind of persistent weakness usually forces investors to revisit the long term story. See our latest analysis for Camping World Holdings. The latest slide, including a steep 90 day share price return of minus 42.53 percent and a 1 year total shareholder return of minus 52.49 percent, signals fading momentum as investors reassess both cyclical risks and the valuation...

Syndax Pharmaceuticals recently showcased new clinical data for its FDA‑approved menin inhibitor Revuforj (revumenib) across the acute leukemia treatment continuum at the 67th American Society of Hematology (ASH) Annual Meeting, and the drug was named Best New Drug at the 2025 Scrip Awards. This combination of high‑profile scientific visibility and industry recognition underscores Revuforj’s role in Syndax’s emerging oncology franchise and highlights the company’s broader progress in...

If you have been wondering whether Addus HomeCare at around $115 a share is a quiet bargain or a value trap, you are not alone. This stock often flies under the radar despite operating in a steadily growing home health market. The share price has inched up about 2.6% over the last week and 5.6% over the past month, but is still down 7.3% year to date and 11.9% over the last year, a mix that hints at recovering sentiment after a softer stretch. Recent headlines have focused on Addus expanding...

Earlier in 2025, Repligen Corporation expanded its bioprocessing portfolio by launching three high-performance chromatography resins: AVIPure HiPer AAV9 and AAV8 affinity resins, plus the HiPer QA anion exchange resin, aimed at advancing gene therapy purification and process efficiency. This move strengthens Repligen’s position in next-generation bioprocessing by broadening its consumables offering, potentially increasing recurring revenue as gene therapy pipelines mature. We’ll now examine...

Earlier this month, Stellantis’ Citroën brand announced a collaboration with Goodyear to develop the Eagle Xplore concept tire, integrating Goodyear’s SightLine technology so tires can monitor their own condition and share real-time data with the vehicle and driver. This partnership underlines Goodyear’s push to embed smart, connected tire systems into software-driven vehicles, potentially shifting its role from a traditional component supplier to a data and technology partner for...

Brink's (BCO) just rolled out a new 750 million dollar share repurchase plan, a sizable slice of its market value. The move signals management’s confidence in cash generation, capital discipline, and the company’s long term growth strategy. See our latest analysis for Brink's. The announcement fits neatly into a strong run, with Brink's posting a roughly 30 percent year to date share price return and a powerful three year total shareholder return above 130 percent, suggesting positive...

Diebold Nixdorf recently announced that Capital Bank, a leading Jordanian financial institution, has rolled out its VCP-Pro 7 software on Microsoft Windows 11-powered ATMs across its network, marking the first such deployment in the Asia Pacific, Middle East and Africa region and supporting the bank’s broader digital and lifecycle management upgrades. Alongside this, the launch of the DN Series 300 and 350 cash dispensers, already piloted by major banks, underlines how Diebold Nixdorf is...

Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through about 2041–2042. This move broadens Royalty Pharma’s exposure to next-generation lung cancer treatments targeting ALK and ROS1 mutations, underscoring its focus on late-stage oncology innovation. We’ll now examine how this oncology-focused royalty acquisition could influence Royalty Pharma’s...

On 15 December 2025, Nektar Therapeutics held an investor call to review topline 36-week induction data from its ongoing Phase 2b REZOLVE-AA trial of rezpegaldesleukin, an investigational Treg-proliferating therapy for severe-to-very-severe alopecia areata. This readout is important because it offers an early test of whether Nektar’s lead immune-modulating asset can show meaningful benefit in a high-need dermatology indication. We’ll now examine how this Phase 2b rezpegaldesleukin readout in...

Wondering if Sprinklr is quietly turning into a value opportunity while everyone chases the flashier software names? Let us break down what the current share price really implies about its future. Sprinklr shares now trade at about $7.71, with the stock down 0.4% over the last week but up 5.9% across the past month, hinting at shifting sentiment even as the year to date return sits at -9.7% and the 1 year return at -18.2%. Recent headlines have focused on Sprinklr expanding its AI powered...

Timken (TKR) has been quietly grinding higher, with the stock up around 14% over the past month and 25% year to date, as investors warm to its steady industrial growth story. See our latest analysis for Timken. The recent climb, including a roughly 14% 1 month share price return and an 18.52% 1 year total shareholder return, signals investors are increasingly backing Timken’s modest growth profile and easing some earlier valuation worries. If Timken’s steady uptrend has you reassessing your...

Recently filed SEC reports reveal that activist investors have taken positions in Impinj, signaling potential pressure on the company’s governance and strategic direction. This new activist presence could influence how Impinj balances growth investments, customer concentration risks, and profitability goals highlighted in existing analyst expectations. We’ll now explore how activist involvement pressing for governance or strategic changes could reshape Impinj’s existing investment narrative...

Mizuho’s new coverage on Marsh and McLennan Companies (MMC) spotlights three levers investors care about: ongoing margin gains, the Thrive restructuring plan, and a fresh 6 billion dollars buyback alongside expansion in Hawai’i. See our latest analysis for Marsh & McLennan Companies. Those moves come as the share price trades around 187.3 dollars, with a modest positive near term share price return but a weaker year to date backdrop. At the same time, multi year total shareholder returns...

DiamondRock Hospitality (DRH) has quietly outperformed many real estate peers this year, with shares up about 15% over the past 3 months as investors revisit hotel focused REITs. See our latest analysis for DiamondRock Hospitality. That recent 90 day share price return of about 14.6% builds on a steadier year to date rise. The one year total shareholder return of roughly 1.6% suggests momentum is only just starting to turn more constructive as investors reassess hotel REIT risk and recovery...